Financhill
Sell
32

CHRO Quote, Financials, Valuation and Earnings

Last price:
$1.25
Seasonality move :
-22.86%
Day range:
$1.06 - $1.28
52-week range:
$0.45 - $3.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
71.2K
Avg. volume:
1.4M
1-year change:
-29.38%
Market cap:
$7.2M
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Channel Therapeutics has 580% upside to fair value with a price target of -- per share.

CHRO vs. S&P 500

  • Over the past 5 trading days, Channel Therapeutics has underperformed the S&P 500 by -10.04% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Channel Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Channel Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Channel Therapeutics reported revenues of --.

Earnings Growth

  • Channel Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Channel Therapeutics reported earnings per share of --.
Enterprise value:
8.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2021-09-30 2022-09-30 2023-09-30 2022-09-30 2023-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -$1.3M -$4.2M -$518.8K -$1.3M
EBITDA -- -$1.3M -$4.2M -$518.8K -$1.3M
Diluted EPS -- -$0.15 -$0.66 -$0.06 -$0.25
Period Ending 2019-09-30 2020-09-30 2021-09-30 2022-09-30 2023-09-30
Balance Sheet
Current Assets -- -- -- $173.2K $22.8K
Total Assets -- -- -- $44.5M $22.8K
Current Liabilities -- -- -- $3.2M $5.9M
Total Liabilities -- -- -- $3.2M $5.9M
Total Equity -- -- -- $41.3M -$5.9M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2021-09-30 2022-09-30 2023-09-30 2022-09-30 2023-09-30
Cash Flow Statement
Cash Flow Operations -- -- -$1.3M -$257.8K -$257.2K
Cash From Investing -- -- -- -- --
Cash From Financing -- -- $1.1M $428.6K $198.1K
Free Cash Flow -- -- -$1.3M -$257.8K -$257.2K
CHRO
Sector
Market Cap
$7.2M
$35.8M
Price % of 52-Week High
32.9%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-29.38%
-38.63%
Beta (5-Year)
--
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.33
200-day SMA
Buy
Level $1.12
Bollinger Bands (100)
Sell
Level 0.88 - 2
Chaikin Money Flow
Sell
Level -26.8M
20-day SMA
Sell
Level $1.36
Relative Strength Index (RSI14)
Sell
Level 44.19
ADX Line
Buy
Level 21.87
Williams %R
Buy
Level -85.5027
50-day SMA
Sell
Level $1.59
MACD (12, 26)
Sell
Level -0.07
25-day Aroon Oscillator
Sell
Level -36
On Balance Volume
Neutral
Level 88.1M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Stock Forecast FAQ

In the current month, CHRO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CHRO average analyst price target in the past 3 months is --.

  • Where Will Channel Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Channel Therapeutics share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Channel Therapeutics?

    Analysts are divided on their view about Channel Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Channel Therapeutics is a Sell and believe this share price will drop from its current level to --.

  • What Is Channel Therapeutics's Price Target?

    The price target for Channel Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CHRO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Channel Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of CHRO?

    You can purchase shares of Channel Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Channel Therapeutics shares.

  • What Is The Channel Therapeutics Share Price Today?

    Channel Therapeutics was last trading at $1.25 per share. This represents the most recent stock quote for Channel Therapeutics. Yesterday, Channel Therapeutics closed at $1.25 per share.

  • How To Buy Channel Therapeutics Stock Online?

    In order to purchase Channel Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
36
WGS alert for May 2

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
42
VICR alert for May 2

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock